These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
496 related articles for article (PubMed ID: 30315932)
1. YM155 sensitizes non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitors through the mechanism of autophagy induction. Dai CH; Shu Y; Chen P; Wu JN; Zhu LH; Yuan RX; Long WG; Zhu YM; Li J Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3786-3798. PubMed ID: 30315932 [TBL] [Abstract][Full Text] [Related]
2. Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin. Okamoto K; Okamoto I; Hatashita E; Kuwata K; Yamaguchi H; Kita A; Yamanaka K; Ono M; Nakagawa K Mol Cancer Ther; 2012 Jan; 11(1):204-13. PubMed ID: 22075159 [TBL] [Abstract][Full Text] [Related]
3. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374 [TBL] [Abstract][Full Text] [Related]
4. Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer. Shimizu T; Nishio K; Sakai K; Okamoto I; Okamoto K; Takeda M; Morishita M; Nakagawa K Cancer Chemother Pharmacol; 2020 Aug; 86(2):211-219. PubMed ID: 32638093 [TBL] [Abstract][Full Text] [Related]
6. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death. Chen P; Huang HP; Wang Y; Jin J; Long WG; Chen K; Zhao XH; Chen CG; Li J J Exp Clin Cancer Res; 2019 Jun; 38(1):254. PubMed ID: 31196210 [TBL] [Abstract][Full Text] [Related]
7. Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway. Wang H; Du X; Liu W; Zhang C; Li Y; Hou J; Yu Y; Li G; Wang Q Respir Res; 2024 May; 25(1):215. PubMed ID: 38764025 [TBL] [Abstract][Full Text] [Related]
8. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer. Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010 [TBL] [Abstract][Full Text] [Related]
9. Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy. Li YL; Hu X; Li QY; Wang F; Zhang B; Ding K; Tan BQ; Lin NM; Zhang C Mol Med Rep; 2018 Oct; 18(4):3882-3890. PubMed ID: 30106133 [TBL] [Abstract][Full Text] [Related]
13. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer. Smith DL; Acquaviva J; Sequeira M; Jimenez JP; Zhang C; Sang J; Bates RC; Proia DA Target Oncol; 2015 Jun; 10(2):235-45. PubMed ID: 25077897 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo. Yu W; Lu W; Chen G; Cheng F; Su H; Chen Y; Liu M; Pang X Br J Pharmacol; 2017 Oct; 174(20):3608-3622. PubMed ID: 28749535 [TBL] [Abstract][Full Text] [Related]
15. [Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650]. Han R; Wang X; Zhong D; Zhao J; Chen Z; Sun L; Wang J; Zhang J Zhongguo Fei Ai Za Zhi; 2012 Dec; 15(12):689-93. PubMed ID: 23249714 [TBL] [Abstract][Full Text] [Related]
16. Targeting Epidermal Growth Factor Receptor by MiRNA-145 Inhibits Cell Growth and Sensitizes NSCLC Cells to Erlotinib. Amri J; Molaee N; Baazm M; Karami H Asian Pac J Cancer Prev; 2019 Sep; 20(9):2781-2787. PubMed ID: 31554377 [TBL] [Abstract][Full Text] [Related]
17. Autophagy inhibition facilitates erlotinib cytotoxicity in lung cancer cells through modulation of endoplasmic reticulum stress. Wang Z; Du T; Dong X; Li Z; Wu G; Zhang R Int J Oncol; 2016 Jun; 48(6):2558-66. PubMed ID: 27035631 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of JAK1/2 can overcome EGFR-TKI resistance in human NSCLC. Kim DM; Kim MJ; Moon JH; Lee EY; Hong JK; Lee S; Koh DI; Ryu YS; Kim SM; Jung SA; Shin JS; Kim J; Park YS; Hong SW; Lee SH; Jung J; Park SS; Kim DY; Kim EH; Jeong HR; Gong JH; Kim J; Chan Kim S; Yu HN; Ki SY; Kim TW; Jin DH Biochem Biophys Res Commun; 2020 Jun; 527(1):305-310. PubMed ID: 32446385 [TBL] [Abstract][Full Text] [Related]
19. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations. Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992 [TBL] [Abstract][Full Text] [Related]
20. Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR. Hwang KE; Kwon SJ; Kim YS; Park DS; Kim BR; Yoon KH; Jeong ET; Kim HR Exp Cell Res; 2014 May; 323(2):288-96. PubMed ID: 24631288 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]